<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Systemic therapy for metastatic colorectal cancer: General principles</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Systemic therapy for metastatic colorectal cancer: General principles</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Systemic therapy for metastatic colorectal cancer: General principles</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey W Clark, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Hanna K Sanoff, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard M Goldberg, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H183911197"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Most patients with metastatic colorectal cancer (mCRC) are treated with systemic therapy. This topic will discuss general principles of systemic treatment for mCRC. Specific details on the approach to initial and subsequent systemic therapy in unresectable mCRC are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/129349.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2512.html" rel="external">"Therapy for metastatic colorectal cancer in older adult patients and those with a poor performance status"</a>.)</p><p></p><p class="headingAnchor" id="H1984345359"><span class="h1">SYSTEMIC THERAPY</span></p><p class="headingAnchor" id="H7582384"><span class="h2">Available agents</span><span class="headingEndMark"> — </span>Many systemic agents are used to treat mCRC, in combination with other drugs and as monotherapy. These include chemotherapy (<a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> [FU], <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a>, <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a>, among others), antiangiogenic agents, molecularly targeted agents, and immune checkpoint inhibitors. Available agents that are used as part of initial therapy and later lines of therapy for mCRC are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'Available agents and strategy for selection of the approach'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/129349.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy", section on 'Available agents and overview of the therapeutic approach'</a>.)</p><p></p><p>Many patients with mCRC are treated with initial combination systemic therapy, particularly those whose metastases might be potentially resectable after an initial response to chemotherapy. This approach must take into account the potential toxicities of combination therapy. Further details are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'Candidates for intensive systemic therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2483.html" rel="external">"Potentially resectable colorectal cancer liver metastases: Integration of surgery and chemotherapy", section on 'Patients with initially unresectable metastases'</a>.)</p><p></p><p></p><p class="headingAnchor" id="H2755770616"><span class="h1">PREDICTIVE BIOMARKERS</span><span class="headingEndMark"> — </span>Predictive biomarkers (specific targetable molecular alterations found in colorectal cancer) are often used to select therapy for mCRC. Gene profiling of tumor tissue (ie, with next-generation sequencing) should be obtained immediately after a diagnosis of mCRC to determine the presence of these molecular alterations, which influence management. </p><p class="headingAnchor" id="H2683315893"><span class="h2"><i>RAS</i></span><span class="headingEndMark"> — </span>Metastatic colorectal cancer (mCRC) tumors are either <em>RAS</em> wild-type or<em> RAS </em>mutated<em>. </em>The molecular genetics and frequency of <em>RAS</em> mutations in mCRC are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2485.html" rel="external">"Molecular genetics of colorectal cancer", section on 'RAS'</a>.)</p><p>Assessing<em> </em>the<em> RAS </em>status of a tumor permits the selection of individuals who might benefit from specific strategies, particularly those targeting the epidermal growth factor receptor (EGFR). </p><p class="headingAnchor" id="H855464093"><span class="h3"><i>RAS</i> testing</span><span class="headingEndMark"> — </span>All patients with mCRC who are eligible for EGFR inhibitors should have tumor tissue tested for mutations in both <em>KRAS</em> and <em>NRAS</em> exons 2 (codons 12 and 13), 3 (codons 59 and 61), and 4 (codons 117 and 146). This is consistent with guidelines from The American Society of Clinical Oncology (ASCO) [<a href="#rid1">1</a>] and the National Comprehensive Cancer Network (NCCN) [<a href="#rid2">2,3</a>]. </p><p>The US Food and Drug Administration has approved several companion diagnostic tests for extended <em>RAS</em> testing (<em>KRAS</em> exons 2,3, and 4 and <em>NRAS</em> exons 2, 3, and 4). These include the PRAXIS Extended RAS Panel, FoundationOne CDx, and xT CDx [<a href="#rid4">4</a>].</p><p>In patients with mCRC, tumor tissue (either from the primary tumor or metastatic sites) remains the gold standard for evaluating for activating <em>RAS</em> mutations. <em>KRAS </em>or <em>NRAS</em> are detected with good concordance between the primary tumor and synchronous distant metastases, but not lymph node metastases [<a href="#rid5">5,6</a>]. However, in some settings, rebiopsy of metastases for <em>RAS</em> mutation analysis may be warranted. In observational studies of patients with colorectal cancer that assessed <em>RAS</em> mutations in the primary tumor versus recurrent tumors, the rate of discordant results in <em>RAS</em> status was estimated at 20 percent [<a href="#rid7">7</a>]. </p><p class="headingAnchor" id="H676544459"><span class="h3">What is the role of ctDNA?</span><span class="headingEndMark"> — </span>The use of circulating tumor DNA (ctDNA) to confirm <em>RAS</em> mutation status in mCRC is evolving. Further data are necessary prior to the routine use of ctDNA to select treatment for mCRC, as some studies suggest discordance between the genotyping results on tissue versus ctDNA. Tumor tissue genotyping should be used to confirm the results from ctDNA testing, if obtained. For patients where access to tissue is unavailable or difficult to obtain, treatment may be based on actionable alterations identified on ctDNA analysis [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/z/d/html/129349.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy", section on 'Multipanel somatic (tumor) and germline genomic testing'</a>.)</p><p>The use of ctDNA (or "liquid biopsy") obtained from the blood of patients with cancer can be used to detect and quantify tumor-specific genetic alterations, including <em>RAS</em> mutations. One advantage of ctDNA is the potential for reducing turnaround time on mutation results, although this is based on retrospective data with a limited number of cases [<a href="#rid9">9</a>]. </p><p>Studies are also conflicting for concordance between the genotyping results of ctDNA assays and tumor specimens. In some studies, the overall concordance between tumor and plasma <em>RAS</em> mutational status (a summation of true positives and true negatives) is 82 to 93 percent [<a href="#rid9">9-15</a>]. However, other studies have reported lower rates of concordance (64 to 78 percent), especially in certain metastatic sites including the lung and peritoneum [<a href="#rid9">9,12,16</a>]. In one meta-analysis of 21 studies evaluating the effectiveness of ctDNA for detection of <em>KRAS</em> mutations, sensitivity and specificity were 67 and 96 percent, respectively [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H1792633915"><span class="h3">Impact of <i>RAS</i> status on the use of EGFR inhibitors</span><span class="headingEndMark"> — </span>For patients with mCRC whose tumors are <em>RAS</em> mutant, we do not use epidermal growth factor receptor (EGFR) inhibitors (<a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> or <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a>) either alone or in addition to chemotherapy. Tumors that harbor activating mutations in<em> RAS </em>(most commonly <em>KRAS</em> but also <em>NRAS</em>) are resistant to EGFR inhibitors due to constitutive activation of the <em>RAS</em> pathway. Clinical trials also confirm that EGFR inhibitors have limited clinical benefit or inferior survival outcomes in <em>RAS</em>-mutated CRC. (See  <a class="medical medical_review" href="/z/d/html/2485.html" rel="external">"Molecular genetics of colorectal cancer", section on 'Molecular mechanism of RAS mutations'</a>.)</p><p>By contrast, patients with mCRC and whose tumors are <em>RAS</em> and <em>BRAF</em> V600E wild-type are eligible for treatment with EGFR inhibitors (<a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> or <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a>). (See  <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'RAS/BRAF wild-type tumors'</a> and  <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'Benefit of cetuximab and panitumumab'</a>.)</p><p>Clinical studies in patients with <em>RAS</em>-mutated mCRC have demonstrated no benefit for EGFR inhibitors. Data are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>KRAS</em></strong><strong> mutations in exon 2</strong> – The most common <em>RAS</em> mutations in mCRC are<em> KRAS</em> mutations in exon 2 (codons 12 and 13). Patients with these tumors derive limited benefit from the use of EGFR inhibitor-based therapy [<a href="#rid17">17-29</a>]. In addition, some studies also demonstrated inferior progression-free survival (PFS) with this approach [<a href="#rid19">19,30</a>]. As examples:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a systematic review of four randomized trials [<a href="#rid18">18,19</a>], among patients with <em>KRAS</em> exon 2 mutant mCRC, the addition of an EGFR inhibitor to either chemotherapy (for treatment-naïve mCRC in the CRYSTAL and OPUS trials [<a href="#rid18">18,19</a>]) or best supportive care (for treatment-refractory mCRC in the C0.17 trial and in another trial [<a href="#rid20">20,23</a>]) did not confer a PFS (hazard ratio [HR] 1.0) or overall survival (OS; HR 1.0) advantage [<a href="#rid28">28</a>]. Further details on these individual trials are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'Benefit of cetuximab and panitumumab'</a> and  <a class="medical medical_review" href="/z/d/html/129349.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy", section on 'No prior initial therapy with cetuximab/panitumumab'</a> and  <a class="medical medical_review" href="/z/d/html/2483.html" rel="external">"Potentially resectable colorectal cancer liver metastases: Integration of surgery and chemotherapy", section on 'RAS/BRAF wild-type disease'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A randomized phase III trial (PRIME) of patients with previously untreated mCRC included a subgroup of 440 patients with <em>KRAS</em> exon 2 mutations. In this subgroup, the addition of <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a> to FOLFOX worsened PFS (median 7.3 versus 8.8 months, HR 1.29, 95% CI 1.04-1.62) and failed to improve OS (median 16 versus 19 months, HR 1.24, 95% CI 0.98-1.57) [<a href="#rid30">30</a>]. Further details on the PRIME trial are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'Benefit of cetuximab and panitumumab'</a>.) </p><p></p><p class="bulletIndent2">Similar results were also seen in a separate randomized phase II trial (OPUS) evaluating the addition of <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> to FOLFOX. In this study, among the subgroup of 99 patients with <em>KRAS</em> exon 2 mutated tumors, FOLFOX plus cetuximab resulted in inferior PFS relative to FOLFOX alone (median PFS 6 versus 9 months, HR 1.83, 95% CI 1.10 to 3.06) [<a href="#rid19">19</a>]. Further details on the OPUS trial are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2483.html" rel="external">"Potentially resectable colorectal cancer liver metastases: Integration of surgery and chemotherapy", section on 'RAS/BRAF wild-type disease'</a>.)</p><p></p><p class="bulletIndent1">The <em>KRAS</em> G13D mutation may be an exception. Data, including several meta-analyses, are conflicting are conflicting as to whether this mutation confers resistance to EGFR inhibitors or not [<a href="#rid31">31-37</a>].</p><p></p><p class="bulletIndent1">KRAS G12C inhibitors are being investigated alone and in combination with other agents in patients with <em>KRAS</em> G12C mutated mCRC. Further details are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/129349.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy", section on 'RAS-mutated tumors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other </strong><strong><em>RAS</em></strong><strong> mutations</strong> – Similarly, tumors with lower frequency <em>KRAS</em> mutations outside of exon 2 and <em>NRAS</em> mutations also do not benefit from EGFR inhibitors [<a href="#rid6">6,25,38-44</a>]. As examples,</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a meta-analysis of nine randomized trials that evaluated EGFR inhibitor-based therapy in mCRC, no difference in PFS or OS benefit was demonstrated between tumors with <em>RAS</em> mutations other than exon 2 (<em>KRAS</em> exon 3 and 4 and <em>NRAS</em> exons 2, 3, and 4) and tumors with <em>KRAS</em> exon 2 mutations [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a subgroup analysis of the PRIME trial by mutational status, relative to the absence of a <em>RAS</em> mutation, <em>RAS</em> mutations other than <em>KRAS</em> exon 2 was a negative effect modifier for the addition of <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a> to FOLFOX on both OS and PFS [<a href="#rid38">38</a>]. These data suggest that <em>RAS</em> mutations outside of exon 2 are also negative predictive factors for survival. </p><p></p><p class="headingAnchor" id="H3965903482"><span class="h2"><i>BRAF</i> mutations</span><span class="headingEndMark"> — </span>For patients with mCRC that are <em>BRAF</em> V600E mutated and <em>RAS</em> wild-type, we do not use EGFR inhibitors (<a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> or <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a>) as single agents in this population. This mutation induces resistance to EGFR inhibitors, and randomized trials conducted in this population suggest limited benefits. This approach is consistent with guidelines from the American Joint Committee on Cancer (AJCC) [<a href="#rid45">45</a>], NCCN [<a href="#rid2">2</a>], and European Society for Medical Oncology (ESMO) [<a href="#rid46">46</a>].</p><p>For those with treatment-refractory disease, <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> or <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a> can be combined with <a class="drug drug_general" data-topicid="118325" href="/z/d/drug information/118325.html" rel="external">encorafenib</a>, a BRAF inhibitor, to overcome tumor resistance to EGFR inhibitors. Further details are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/129349.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy", section on 'RAS wild-type, BRAF mutated tumors'</a>.)</p><p><em>BRAF</em> is a component of the RAS-RAF-MAPK signaling pathway. Activating <em>BRAF</em> mutations, which are mutually exclusive with <em>KRAS</em> mutations, are found in approximately 5 to 12 percent of mCRCs. <em>BRAF</em> mutations (most of which are V600E mutations) have consistently been associated with poor prognosis in mCRC [<a href="#rid47">47-53</a>]. (See  <a class="medical medical_review" href="/z/d/html/2484.html" rel="external">"Pathology and prognostic determinants of colorectal cancer", section on 'RAS and BRAF'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>V600E mutations</strong> – Studies demonstrate that a response to EGFR inhibitors (either alone or in combination with chemotherapy) is unlikely in patients whose tumors harbor <em>BRAF</em> V600E mutations, even if they are <em>RAS</em> wild-type [<a href="#rid54">54-56</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>One analysis of 10 randomized trials comparing <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> or <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a> alone or plus chemotherapy with standard therapy or best supportive care included one phase II and nine phase III trials; six were conducted in the first-line treatment setting, two for second-line therapy, and two in patients with chemorefractory disease [<a href="#rid54">54</a>]. Among patients with <em>RAS </em>wild-type/<em>BRAF </em>V600E mutant tumors, compared with control regimens, the addition of an anti-EGFR monoclonal antibody did not significantly improve PFS (hazard ratio [HR] 0.88, 95% CI 0.67-1.14), OS (HR 0.91, 95% CI 0.62-1.34), or objective response rate.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A similar conclusion was reached in an individual patient data analysis derived from the ARCAD database of ten randomized trials of first-line targeted therapies [<a href="#rid56">56</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Another analysis included eight randomized trials, four conducted in the first-line setting, three in the second-line setting, and one in patients with chemorefractory disease [<a href="#rid55">55</a>]. Among patients with <em>RAS </em>wild-type/<em>BRAF </em>V600E mutant mCRC, there was no significant overall survival benefit for the addition of an anti-EGFR monoclonal antibodies (HR 0.97, 95% CI 0.67-1.41). By contrast, overall survival was significantly greater in patients with <em>RAS </em>wild-type <em>BRAF </em>wild-type tumors (HR 0.81, 95% CI 0.7-0.95). When comparing the overall survival benefit between <em>BRAF </em>V600E mutant and <em>BRAF </em>wild-type tumors, the test for interaction was not statistically significant, leading the authors to conclude that the observed differences in the effect of anti-EGFR monoclonal antibodies on overall survival according to <em>BRAF </em>V600E mutation status could have been due to chance, and that the evidence was insufficient to state that mutant tumors attain a different treatment benefit from anti-EGFR agents compared with individuals with <em>BRAF </em>wild-type tumors.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a phase II trial (FIRE-4.5; AIO KRK0016), 109 patients with previously untreated <em>RAS </em>wild-type <em>BRAF </em>V600E-mutated mCRC were randomly assigned to <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> plus <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a>, <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a>, and short-term infusional <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> (FU; FOLFOXIRI) plus either <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> or <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> [<a href="#rid57">57</a>]. Compared with FOLFOXIRI plus bevacizumab, FOLFOXIRI plus cetuximab decreased the objective response rate (51 versus 67 percent) and PFS (median 7 versus 11 months, HR 1.89). There was a nonstatistically significant trend towards inferior overall survival for FOLFOXIRI plus cetuximab (median 13 versus 17 months). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other </strong><strong><em>BRAF</em></strong><strong> mutations</strong> – Less is known about <em>BRAF</em> mutations outside of codon 600, which account for about one-fifth of all <em>BRAF </em>mutations in mCRC [<a href="#rid58">58</a>]. From a prognostic standpoint, patients with mCRC whose tumors harbor a non-V600 mutation seem to have a better median overall survival than do those with either a V600E mutation or a <em>BRAF </em>wild-type tumor (61 versus 11 versus 43 months, respectively) [<a href="#rid58">58</a>]. However, there are very few data addressing the predictive value of non-V600 <em>BRAF</em> mutations for response to anti-EGFR agents [<a href="#rid59">59-61</a>], and this remains an area of active investigation. (See  <a class="medical medical_review" href="/z/d/html/2484.html" rel="external">"Pathology and prognostic determinants of colorectal cancer", section on 'RAS and BRAF'</a>.)</p><p></p><p class="headingAnchor" id="H2901778380"><span class="h2">dMMR or MSI-H tumors</span><span class="headingEndMark"> — </span>Approximately 3.5 to 6.5 percent of stage IV CRCs have mismatch repair deficient (dMMR) enzymes, the biologic footprint of which is microsatellite instability high (MSI-H). Cancers with dMMR/MSI-H appear to be uniquely susceptible to immune checkpoint inhibitors, and this is a reasonable first-line approach for appropriately selected patients. (See  <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'Patients with deficient DNA mismatch repair/microsatellite unstable tumors'</a> and  <a class="medical medical_review" href="/z/d/html/120646.html" rel="external">"Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors", section on 'Biology of mismatch repair and tumor mutational burden'</a>.)</p><p class="headingAnchor" id="H422996599"><span class="h2">HER2-positive tumors</span><span class="headingEndMark"> — </span>Approximately 3 to 5 percent of CRCs have amplification of the human epidermal growth factor receptor 2 (<em>HER2</em>) oncogene or overexpress its protein product, HER2. HER2-targeted therapies are used to treat patients with HER2-overexpressing mCRC who progress on conventional chemotherapy. Further details on available agents are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/129349.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy", section on 'RAS wild-type, HER2 overexpressors'</a>.)</p><p>HER2-targeted therapy may also be considered as a first-line treatment in patients who are not candidates for more intensive therapy; however, it is not our preferred approach. (See  <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'Not candidates for intensive therapy'</a>.)</p><p class="headingAnchor" id="H3220388459"><span class="h2">TRK-fusion-positive tumors</span><span class="headingEndMark"> — </span>Tumors that harbor molecular alterations in the neurotrophic tyrosine receptor kinas<em>e (NTRK</em>) gene produce tropomyosin receptor kinase (TRK) fusion oncoproteins. Such tumors can be treated with agents that target these TRK fusion oncoproteins, such as <a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">larotrectinib</a> or <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">entrectinib</a>. Further details are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/122713.html" rel="external">"TRK fusion-positive cancers and TRK inhibitor therapy"</a>.)</p><p class="headingAnchor" id="H3959811778"><span class="h2">Other biomarkers</span><span class="headingEndMark"> — </span><em>EGFR</em> amplification is not an established predictive biomarker for mCRC. Some [<a href="#rid62">62-64</a>], but not all studies [<a href="#rid21">21,65-67</a>], suggest an association between <em>EGFR</em> copy number and response to EGFR inhibitors. However, the clinical use of <em>EGFR</em> amplification to select patients for therapy is limited by the lack of standardization of fluorescence in situ hybridization technology and scoring [<a href="#rid63">63,66</a>].</p><p class="headingAnchor" id="H9654617"><span class="h1">TREATMENT GOALS</span><span class="headingEndMark"> — </span>The goals of chemotherapy for mCRC differ according to the clinical scenario. For most patients, treatment will be palliative and not curative (a fact that may not be understood by patients [<a href="#rid68">68</a>]), and the treatment goals are to prolong overall survival (OS) and maintain quality of life (QOL) for as long as possible.</p><p class="headingAnchor" id="H9654802"><span class="h2">Potentially resectable disease</span><span class="headingEndMark"> — </span>However, some patients with stage IV disease (particularly those with liver-limited metastases) can be surgically cured of their disease. Even selected patients with initially unresectable liver metastases may become eligible for resection if the response to chemotherapy is sufficient.</p><p>This approach has been termed "conversion therapy" [<a href="#rid69">69</a>] to distinguish it from "neoadjuvant therapy," which applies to preoperative chemotherapy given to patients who present upfront with apparently resectable disease. The key parameter for selecting the specific regimen in this scenario is not survival or improved QOL, but instead, response rate (ie, the ability of the regimen to shrink metastases) [<a href="#rid70">70</a>]. (See  <a class="medical medical_review" href="/z/d/html/2483.html" rel="external">"Potentially resectable colorectal cancer liver metastases: Integration of surgery and chemotherapy", section on 'Patients with initially unresectable metastases'</a>.)</p><p class="headingAnchor" id="H9654809"><span class="h2">Nonresectable disease</span><span class="headingEndMark"> — </span>The following general principles guide the use of palliative chemotherapy in the setting of nonoperable disease:</p><p class="bulletIndent1"><span class="glyph">●</span>In general, for patients without symptomatic disease (ie, the majority of patients), induction of a tumor response is not as important as is delaying tumor progression for as long as possible. In the palliative setting, objective response rate is not the best indicator of treatment benefit (prolonged survival and/or progression-free survival [PFS]) [<a href="#rid71">71-73</a>]. Thus, achieving stable disease as the best response to therapy might be considered a treatment success. (See <a class="local">'Assessing treatment response'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients benefit more from access to all active agents than from a particular treatment sequence of specific regimens used as individual "lines" of therapy. In all large published phase III trials testing various combinations of cytotoxic agents and targeted agents conducted over the last decade, the proportion of patients receiving all active agents has correlated strongly with median survival [<a href="#rid74">74,75</a>]. Although no such analysis has yet been performed after the introduction of biologic agents, it is conceivable that the overall principle of optimizing outcomes through exposure to all active agents is still valid.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Despite these findings, the available evidence suggests that only a minority of American patients with mCRC are exposed to all active agents in the course of their therapy for mCRC [<a href="#rid76">76</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Because of the survival benefit from second- and even third-line chemotherapy, the routine practice of crossover in clinical trials severely limits the ability to detect an overall survival advantage of one treatment regimen over another. Therefore, the actual activity of a new agent or combination regimen is better captured by the endpoint PFS, in particular in the first-line setting. Improvements in PFS correlate with longer survival [<a href="#rid77">77-79</a>] and are not affected by crossover or subsequent therapy.</p><p></p><p class="bulletIndent1">These concepts can be illustrated by results from the EPIC trial, in which patients failing initial oxaliplatin-based therapy were randomly assigned to <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> with or without <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> [<a href="#rid80">80</a>]. There were significant differences in PFS, objective response, and disease control rates that favored combined therapy, but no overall survival advantage. This was attributed to the fact that 50 percent of the patients in the irinotecan arm crossed over to cetuximab at progression. (See  <a class="medical medical_review" href="/z/d/html/129349.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy", section on 'No prior initial therapy with cetuximab/panitumumab'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Endpoints other than PFS (eg, duration of disease control, time to failure of strategy) have been proposed, but none are widely used [<a href="#rid81">81,82</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The model of distinct "lines" of chemotherapy (in which regimens containing non-cross-resistant drugs are each used in succession until disease progression) is being abandoned in incurable metastatic mCRC in favor of a "continuum of care" approach [<a href="#rid83">83</a>]. This implies an individualized treatment strategy that may include phases of maintenance chemotherapy interspersed with more aggressive treatment protocols, as well as reutilization of previously administered chemotherapy agents in combination with other active drugs.</p><p></p><p>The following sections will emphasize the practical issues that arise when choosing the appropriate treatment strategy for individual patients with inoperable mCRC. Specific recommendations for therapy as well as management of patients with potentially resectable liver metastases are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach"</a> and  <a class="medical medical_review" href="/z/d/html/129349.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy"</a> and  <a class="medical medical_review" href="/z/d/html/2512.html" rel="external">"Therapy for metastatic colorectal cancer in older adult patients and those with a poor performance status"</a> and  <a class="medical medical_review" href="/z/d/html/2483.html" rel="external">"Potentially resectable colorectal cancer liver metastases: Integration of surgery and chemotherapy"</a>.)</p><p class="headingAnchor" id="H183911606"><span class="h1">SYSTEMIC THERAPY VERSUS SUPPORTIVE CARE</span><span class="headingEndMark"> — </span>Systemic <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> (FU)-based chemotherapy produces meaningful improvements in median survival and progression-free survival (PFS) compared with best supportive care (BSC) alone [<a href="#rid84">84-86</a>]. These benefits are most pronounced with regimens containing <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> or <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> in combination with FU. Although no trial has compared these regimens with BSC alone, median survival durations in clinical trials of oxaliplatin- and irinotecan-containing chemotherapy now consistently exceed two years; by contrast, for patients with unresectable mCRC who receive best supportive care (BSC) alone, median survival is approximately five to six months [<a href="#rid84">84-86</a>].</p><p>Long-term survival is improving over time with the availability of more active anticancer agents [<a href="#rid87">87-90</a>]. As an example, in a report of pooled data from North Center Cancer Treatment Group (NCCTG) trials conducted in the FU plus <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> (LV) era, only 1.1 percent of patients were alive at five years [<a href="#rid91">91</a>]. By contrast, in a report from the phase III FIRE-3 trial (first-line <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> with short-term infusional FU plus LV [FOLFIRI] plus either <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> or <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a>), the five-year survival rate for patients with RAS wild-type tumors treated with FOLFIRI plus cetuximab was approximately 20 percent [<a href="#rid92">92</a>]. Although many of the survival gains are attributable to advances in chemotherapy treatment, more aggressive use of surgical resection of metastatic disease has also contributed [<a href="#rid89">89</a>]. (See  <a class="medical medical_review" href="/z/d/html/2483.html" rel="external">"Potentially resectable colorectal cancer liver metastases: Integration of surgery and chemotherapy"</a> and  <a class="medical medical_review" href="/z/d/html/2796.html" rel="external">"Surgical resection of pulmonary metastases: Outcomes by histology", section on 'Colorectal cancer'</a>.)</p><p class="headingAnchor" id="H183911613"><span class="h1">TIMING OF SYSTEMIC THERAPY</span><span class="headingEndMark"> — </span>Although the value of early chemotherapy versus treatment deferral until symptoms develop is controversial, we suggest instituting chemotherapy at diagnosis for patients with categorically unresectable mCRC, and when possible, before patients become symptomatic.</p><p>Many patients with mCRC are asymptomatic. Data are limited on optimal timing of chemotherapy, and the only randomized trials directly addressing this issue studied older regimens like <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> (FU) and <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> (LV):</p><p class="bulletIndent1"><span class="glyph">●</span>In an early trial in which 182 patients with asymptomatic mCRC were randomly assigned to initial or deferred chemotherapy with sequential <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, FU, and LV, earlier treatment was associated with improvements in median survival (14 versus 9 months), symptom-free interval, and progression-free survival (PFS) [<a href="#rid84">84</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a combined analysis of 168 asymptomatic patients who were enrolled in two trials randomly testing early versus delayed FU-based chemotherapy, there was a non-statistically significant two-month benefit in median survival with early treatment (13 versus 11 months) [<a href="#rid93">93</a>].</p><p></p><p>Whether these results can be extrapolated to patients treated with <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a>, <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a>, or biologic therapies, especially in the era of modern diagnostic procedures that can detect lower volume metastatic disease, is unclear. Regimens such as these are associated with clear-cut survival benefits, particularly if patients are serially exposed to all active agents. (See  <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'Initial doublet combinations versus sequential single agents'</a>.)</p><p>The only available data from the era of modern chemotherapy come from a retrospective report of 736 patients with mCRC diagnosed between January 2003 and December 2010 at a single Australian center; 377 (51 percent) received immediate chemotherapy, 167 (23 percent) did not because they were deemed inappropriate for therapy or refused, and 192 (26 percent) adopted a "watch and wait" policy initially, 168 of whom eventually received chemotherapy (at a median of 3.7 months from diagnosis) [<a href="#rid94">94</a>]. Compared with immediate treatment, the fraction of patients in the delayed chemotherapy group who eventually received treatment with all active agents was slightly less (30 versus 39 percent), but the median survival was superior (27 versus 17 months).</p><p>Importantly, these data are not from a randomized trial, and interpretation is limited by the potential for selection bias (ie, patients who had treatment deferred were likely to be those with favorable biology [asymptomatic, lower volume metastatic disease, better performance status]), all of which could have contributed to the longer survival in this group. At least in the United States, most patients institute treatment at a time when they are still asymptomatic from their cancer. An alternate approach, which may be particularly appropriate for asymptomatic elderly patients, is an initial period of observation to judge the tempo of disease progression.</p><p class="headingAnchor" id="H23214887"><span class="h1">CHEMOTHERAPY DOSING IN OBESE PATIENTS</span><span class="headingEndMark"> — </span>For cancer patients with a large body surface area (BSA), chemotherapy drug doses are often reduced because of concern for excess toxicity. However, there is no evidence that fully dosed obese patients experience greater toxicity from chemotherapy for mCRC; furthermore, obese patients who are given reduced doses may have inferior outcomes [<a href="#rid95">95</a>]. Although limited, the available data do not support the policy of routine dose reduction (or capping the maximal BSA to 2.0 m<sup>2</sup>) for obese patients with mCRC. Guidelines from the American Society of Clinical Oncology recommend that full weight-based cytotoxic chemotherapy doses be used to treat obese patients with cancer [<a href="#rid96">96</a>]. (See  <a class="medical medical_review" href="/z/d/html/83810.html" rel="external">"Dosing of anticancer agents in adults", section on 'Dosing for overweight/obese patients'</a>.)</p><p class="headingAnchor" id="H183911620"><span class="h1">CONTINUOUS VERSUS INTERMITTENT THERAPY</span><span class="headingEndMark"> — </span>The optimal duration of initial chemotherapy for unresectable mCRC is controversial. The decision to permit treatment breaks for responding patients must be individualized and based upon the regimen being used, tolerance of and response to chemotherapy, disease bulk and location, symptomatology, and patient preference. For many patients with chemotherapy responsive disease who do not have bulky or severely symptomatic disease, intermittent rather than continuous therapy may mitigate treatment-related toxicity, and does not appear to adversely impact overall survival. For patients initially treated with <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a>, a complete break in therapy represents a valid alternative to fluoropyrimidine-based maintenance chemotherapy without oxaliplatin for patients who have responding or stable disease after the initial course of chemotherapy, particularly for those with a complete clinical response or small-volume metastatic disease.</p><p class="headingAnchor" id="H542338790"><span class="h2">Rationale for intermittent therapy</span><span class="headingEndMark"> — </span>When <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> (FU) was the only treatment alternative, patients generally stayed on treatment until their disease progressed or they developed unacceptable toxicity. This typically meant that patients were treated for four to six months (the median progression-free survival [PFS] duration) and then were placed on supportive care alone until they died (median duration of survival approximately one year).</p><p>Compared with FU alone, newer combinations are more effective (median survival durations now consistently approach two years), but they are also more toxic. This is particularly true for oxaliplatin-containing regimens, which cause cumulative neurotoxicity; several studies have shown that more patients come off of therapy because of toxic effects than because of progressive disease [<a href="#rid97">97,98</a>]. Intermittent rather than continuous chemotherapy has the potential to improve outcomes and reduce toxicity as well as cost.</p><p>However, intermittent therapy may be appropriate for some patients and not others:</p><p class="bulletIndent1"><span class="glyph">●</span>There are many patients with small volume but multiple sites of disease who respond well to chemotherapy or have a prolonged period of disease stability. Even if their disease triples in volume off therapy, they will not likely be symptomatic or develop organ dysfunction. Patients with favorable characteristics may be able to tolerate chemotherapy-free (or at least oxaliplatin-free) intervals of multiple months per year and go on to respond favorably to drugs for many years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>On the other end of the spectrum are patients with retained primary tumors, bulky disease, poor performance scores due to tumor related symptoms, peritoneal disease that may lead to unsalvageable bowel obstruction as the first sign of progression, and those with extensive symptomatic disease who progress through treatment regimens in quick succession with either short-lived responses or no response. These patients may be better approached with continuous chemotherapy. (See  <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'Duration of initial chemotherapy'</a>.)</p><p></p><p>Whether continued chemotherapy provides better outcomes than intermittent therapy to best response followed by a chemotherapy "holiday" has been addressed in several trials, most of which have studied chemotherapy regimens that contain <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a>, a drug that is associated with dose-limiting neurotoxicity. Intermittent oxaliplatin-free therapy can be achieved through a complete break in therapy or the use of a non-oxaliplatin-containing "maintenance regimen." (See  <a class="medical medical_review" href="/z/d/html/2826.html" rel="external">"Overview of neurologic complications of platinum-based chemotherapy", section on 'Cumulative sensory neuropathy'</a> and  <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'FOLFOX versus FOLFIRI'</a>.)</p><p class="headingAnchor" id="H183911634"><span class="h2">Patients receiving oxaliplatin</span><span class="headingEndMark"> — </span>Oxaliplatin-based regimens (eg, FOLFOX [<a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> plus LV and short-term infusional FU]) are commonly used for first-line chemotherapy in mCRC [<a href="#rid76">76</a>]. However, oxaliplatin is associated with a cumulative sensory neuropathy, which may be dose limiting.</p><p>Whether long-term neurotoxicity can by mitigated by intermittent oxaliplatin-free intervals has been addressed in several trials. The following represents an overview of the most important findings.</p><p class="headingAnchor" id="H183911641"><span class="h3">Maintenance fluoropyrimidines only</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>OPTIMOX-1</strong> – The OPTIMOX1 trial randomly assigned 620 previously untreated patients to FOLFOX, administered every two weeks until disease progression (arm A), or FOLFOX  (<a class="graphic graphic_table graphicRef64504" href="/z/d/graphic/64504.html" rel="external">table 1</a>) for six cycles only, followed by reintroduction of <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> at the time of progression after 12 cycles of a non-oxaliplatin-containing maintenance regimen (leucovorin-modulated FU) [<a href="#rid81">81</a>]. The duration of disease control and overall survival between the continuous (arm A) and maintenance (arm B) approaches were very similar (9 versus 8.7 months, and 19.3 versus 21.2 months, respectively). Individuals in arm B had a significantly lower risk of developing grade 3 or 4 toxicity during cycles 6 to 18 (but not overall) [<a href="#rid99">99</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>OPTIMOX-2</strong> – The subsequent OPTIMOX-2 trial was initially designed as a 600 patient phase III trial, but when <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> became available, accrual was halted with 202 patients enrolled [<a href="#rid100">100</a>]. OPTIMOX-2 compared six cycles of modified FOLFOX7 followed by maintenance with FU/LV (arm A) to six cycles of modified FOLFOX7 followed by a complete stop in chemotherapy (arm B). The primary endpoint was the duration of disease control, calculated as the sum of the duration of PFS both following the initial three-month course of modified FOLFOX7 (mFOLFOX7)  (<a class="graphic graphic_table graphicRef64504" href="/z/d/graphic/64504.html" rel="external">table 1</a>), as well as after the subsequent reintroduction of <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a>. An important characteristic of OPTIMOX-2 was that randomization occurred after six cycles of therapy regardless of response, and metastases were allowed to progress back to baseline levels before FOLFOX was reintroduced.</p><p></p><p class="bulletIndent1">Complete discontinuation of therapy seemed to have an adverse impact on prognosis; the group receiving maintenance therapy had significantly longer median duration of disease control and median PFS from the time of randomization; there was also a trend toward improved median overall survival (24 versus 20 months, p = 0.42). These data mandate caution and both careful patient selection and vigilant patient monitoring so that therapy can be reinstated promptly at progression when considering chemotherapy-free intervals.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another multicenter trial, the CONcePT trial, in which patients were randomly assigned to continuous versus intermittent <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> (alternating every eight cycles with and without oxaliplatin) also confirmed the benefit of intermittent rather than continuous oxaliplatin for increasing time on first-line therapy for oxaliplatin/bevacizumab-based combinations [<a href="#rid101">101</a>]. Rates of peripheral sensory neuropathy were significantly lower in the intermittent therapy group.</p><p></p><p class="headingAnchor" id="H2896609520"><span class="h3">Maintenance bevacizumab</span><span class="headingEndMark"> — </span>Several trials have explored the benefit of maintenance <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> in patients initially treated with a bevacizumab-containing regimen, both alone and in combination with a fluoropyrimidine.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bevacizumab</strong><strong> plus a fluoropyrimidine</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>CAIRO3</strong> – The utility of maintenance treatment with <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a> plus <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> was addressed in the Dutch CAIRO3 trial, which randomly assigned 558 patients with stable disease or better after six cycles of XELOX plus bevacizumab who were not eligible for potentially curative metastasectomy to continued capecitabine (625 mg/m<sup>2</sup> twice daily every day) plus bevacizumab (7.5 mg/kg every three weeks) or observation alone [<a href="#rid102">102</a>]. Upon first progression (PFS1), patients in both arms were supposed to be treated with XELOX plus bevacizumab until the second progression (PFS2) per protocol. The primary endpoint was PFS2, which was calculated from the time of randomization. Maintenance therapy was associated with a significantly longer PFS2 (11.7 versus 8.5 months, hazard ratio [HR] 0.67, p&lt;0.0001), and there was a trend toward improved overall survival, as well (median 21.6 versus 18.1 months, HR 0.89, p = 0.22).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>German AIO KRK 0207 trial</strong> – Similarly, a benefit for continued fluoropyrimidine plus <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> as compared with observation alone was also shown in the German AIO KRK 0207 trial, in which patients without progressive disease after six months of <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> plus a fluoropyrimidine and bevacizumab were randomly assigned to maintenance with the same fluoropyrimidine plus bevacizumab, bevacizumab alone, or observation only [<a href="#rid103">103</a>]. The primary endpoint was the "time to failure of strategy" or TFS, which included the duration of maintenance plus the time from reinduction after first progression to a second disease progression. The trial was powered to demonstrate noninferiority with a noninferiority margin set at 3.5 months, corresponding to an HR of 1.42. The median TFS in the fluoropyrimidine plus bevacizumab and observations arms was not significantly different (6.9 and 6.4 months, respectively; HR 1.26, 95% CI 0.99-1.60). However, the observation arm was not non-inferior to fluoropyrimidine plus bevacizumab because the upper limit of the 95 percent confidence interval exceeded the threshold set for non-inferiority (1.43). Notably, few patients in either arm were exposed to reinduction treatment (19 percent with combined therapy, and 46 percent of those undergoing observation), rendering the primary endpoint, TFS, non-informative and clinically irrelevant.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>STOP and GO trial</strong> – A slightly different approach was tested in the Turkish STOP and GO trial, in which, following six cycles of <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> plus XELOX, 123 patients were randomly assigned to continued therapy or discontinuation of <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> and maintenance with bevacizumab plus <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a> until progression [<a href="#rid104">104</a>]. The median PFS was significantly better in the group receiving maintenance therapy with bevacizumab plus capecitabine (11 versus 8.3 months), with less grade 3 or 4 diarrhea (3.3 versus 11.3 percent), hand-foot syndrome (1.6 versus 3.2 percent), and neuropathy (1.6 versus 8.1 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bevacizumab</strong><strong> monotherapy</strong> – For patients who have no disease progression after an initial course of <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> plus oxaliplatin-containing chemotherapy, we suggest not pursuing bevacizumab alone for maintenance therapy; this approach is also not recommended in consensus-based guidelines for the treatment of mCRC from the National Comprehensive Cancer Network (NCCN) [<a href="#rid2">2</a>] and European Society for Medical Oncology (ESMO) [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1">The role of maintenance <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> alone has been studied in three trials, all of which used different comparator arms, and all of which came to different conclusions:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>MACRO</strong> – In the Spanish MACRO trial, patients received six cycles of first-line XELOX plus <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> followed by a randomization to continued therapy or bevacizumab maintenance therapy alone until progression or treatment intolerance [<a href="#rid105">105</a>]. There was no arm in which patients received no maintenance therapy. The median PFS and overall survival durations in patients treated with maintenance bevacizumab alone were not significantly worse, and rates of severe neurotoxicity, hand-foot syndrome, and fatigue were significantly lower. However, the trial failed to achieve its primary endpoint of non-inferiority for PFS, because the projected upper limit of the 95 percent confidence interval for PFS exceeded the preset limit.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>SAKK 41-06</strong> – In the Swiss SAKK 41-06 trial, 262 patients with mCRC were randomly assigned to <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> continuation versus no maintenance after four to six months of first-line bevacizumab-containing chemotherapy (62 percent oxaliplatin-containing, 31 percent irinotecan-containing, and the rest fluoropyrimidine alone) [<a href="#rid106">106</a>]. Like the MACRO trial, the trial failed to achieve its primary endpoint of non-inferiority for TTP with the projected upper limit of the 95 percent confidence interval for TTP exceeding the preset limit. The median TTP was 4.1 for bevacizumab continuation versus 2.9 months for no continuation (HR 0.74, 95% CI 0.57-0.95). However, in our view, this study has significant limitations; it includes trials conducted over almost two decades, contains a very heterogenous patient population, and it is heavily influenced by the COIN trial due to its size. As a result, it should not be used to justify use of bevacizumab alone as effective maintenance therapy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>German AIO KRK 0207 trial</strong> – On the other hand, noninferiority of <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> alone compared with bevacizumab plus a fluoropyrimidine was shown in the German AIO KRK 0207 trial, described above [<a href="#rid103">103</a>]. The primary endpoint (the median time to failure of strategy, TFS) in the fluoropyrimidine plus bevacizumab and bevacizumab alone arms was 6.9 and 6.1 months, respectively. Compared with fluoropyrimidine plus bevacizumab, the bevacizumab only arm was non-inferior (HR 1.08, 95% CI 0.85-1.37). However, the upper boundary of the noninferiority margin was very generous (HR 1.43). Notably, few patients in either arm were exposed to reinduction treatment (19 percent with combined therapy, and 43 percent of those receiving bevacizumab alone), rendering the primary endpoint, TFS, non-informative and clinically irrelevant.</p><p></p><p class="headingAnchor" id="H627480129"><span class="h3">Patients initially treated with an EGFR inhibitor</span><span class="headingEndMark"> — </span>For patients initially treated with an agent targeting the epidermal growth factor receptor (EGFR), we suggest maintenance therapy using FU plus the anti-EGFR agent rather than an anti-EGFR agent or fluoropyrimidine alone.</p><p>Benefit from anti-EGFR therapies is limited to patients whose tumors lack mutations in one of the RAS oncogenes (ie, wild-type <em>RAS</em>). (See <a class="local">'RAS'</a> above.)</p><p>Three trials have addressed the benefit of maintenance therapy with an EGFR inhibitor after initial treatment with FOLFOX plus an EGFR inhibitor:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>MACRO </strong>– The phase II MACRO-2 trial randomly assigned 193 patients with <em>KRAS</em> (exon 2 only) wild-type tumors to receive FOLFOX plus <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> for four months (eight courses) followed by either continued therapy with the same regimen or cetuximab monotherapy alone (250 mg/m<sup>2</sup> weekly) [<a href="#rid107">107</a>]. Cetuximab monotherapy was noninferior to the combination of continued FOLFOX plus cetuximab, as judged by the primary endpoint, the proportion of patients who were progression free at nine months (60 versus 72 percent, HR 0.60, 95% CI 0.31-1.15).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>VALENTINO</strong> – On the other hand, results with <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a> alone were inferior to maintenance treatment with FU/LV plus panitumumab following four months of induction therapy with FOLFOX plus panitumumab in the phase II noninferiority VALENTINO trial [<a href="#rid108">108</a>]. Ten-month PFS was inferior with panitumumab alone (49 versus 60 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PANAMA</strong> – A slightly different question, the benefit of adding <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a> to <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> (LV) modulated FU versus FU/LV alone after six cycles of induction therapy with FOLFOX plus panitumumab in <em>RAS</em> wild-type advanced CRC was addressed in the phase III PANAMA trial [<a href="#rid109">109</a>]. Median PFS, the primary endpoint, was significantly better with combined therapy as compared with leucovorin-modulated FU alone (8.8 versus 5.7 months, HR 0.72, 95% CI 0.60-0.85), and there was also a trend to better overall survival that also favored maintenance panitumumab.</p><p></p><p class="headingAnchor" id="H1632309"><span class="h2">Irinotecan</span><span class="headingEndMark"> — </span>While intermittent treatment approaches appear to be almost mandatory for the majority of patients receiving <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> because of cumulative neurotoxicity, there are no cumulative dose-dependent toxicities from <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a>. For most patients, we treat as long as tumor shrinkage continues and treatment is tolerated. Thereafter, as intermittent treatment does not appear to compromise outcomes, treatment breaks could be considered in responding patients, especially those receiving concomitant therapy with an anti-EGFR agent.</p><p>The benefits/risks of intermittent chemotherapy with an irinotecan-containing regimen have been addressed in the following reports:</p><p class="bulletIndent1"><span class="glyph">●</span>One trial demonstrated that patients started on FOLFIRI (<a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> with short-term infusional FU plus LV  (<a class="graphic graphic_table graphicRef76300" href="/z/d/graphic/76300.html" rel="external">table 2</a>)) as first-line therapy had similar overall outcome (PFS and overall survival) whether or not the regimen was administered continuously until progression or toxicity or in "two months on/two months off" intervals [<a href="#rid110">110</a>]. The median chemotherapy-free period in the intermittent treatment group was only three months. However, there were no demonstrable differences in treatment-related toxicity between the continuous versus intermittent treatment groups. Of note, further second- and third-line therapy did not follow a "stop-and-go" approach, so that for overall survival, any potential differences obtained in first-line therapy could have been obscured by subsequent treatment. (See  <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'Irinotecan-based regimens'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>On the other hand, patients treated initially with an <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> plus an anti-EGFR agent might benefit from intermittent as compared with continuous therapy. This issue was directly addressed in the prospective IMPROVE trial, in which 137 patients with unresectable, previously untreated <em>RAS</em>/<em>BRAF</em> wild-type mCRC were randomly assigned to FOLFIRI plus <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a> until disease progression on treatment, or a fixed eight cycles followed by a treatment-free interval, and reintroduction of the same regimen at disease progression [<a href="#rid111">111</a>]. In a preliminary report presented at the 2022 annual American Society of Clinical Oncology meeting, at a median follow-up of 18 months, the overall disease control rate was similar with intermittent as compared with continuous therapy (90 versus 94 percent), and more patients were alive without progression at one year with intermittent therapy (60.8 versus 52.1 percent, median PFS 17.1 versus 13.1 months). The intermittent strategy yielded lower rates of grade ≥3 skin toxicity (13 versus 27 percent), and fewer patients discontinuing therapy for toxicity. The results of this study do have the caveat of a relatively small sample size.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A lack of benefit for maintenance <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> versus no treatment until progression following six months of induction FOLFIRI plus bevacizumab was shown in the randomized phase III PRODIGE 9 trial [<a href="#rid112">112</a>].</p><p></p><p class="headingAnchor" id="H2358851375"><span class="h2">Complete break in therapy</span><span class="headingEndMark"> — </span>The data on maintenance therapy described above have led to the general conclusion that some form of maintenance therapy is preferred rather than a complete break in therapy in patients who are responding to or have stable disease after induction chemotherapy therapy. However, while maintenance therapy prolongs PFS compared with no maintenance therapy, none of the trials described above have shown that this approach is associated with better overall survival compared with a complete break in therapy.</p><p>At least two meta-analyses and a more recent trial have specifically addressed the role of observation (ie, a complete break in therapy) versus maintenance treatment in patients initially treated with either <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> or irinotecan-based initial systemic therapy for mCRC, all of which have concluded that overall survival is not adversely impacted by a complete break in treatment:</p><p class="bulletIndent1"><span class="glyph">●</span>A network meta-analysis included 12 randomized trials comparing the different treatment strategies of continued chemotherapy, observation, and maintenance therapy (including fluoropyrimidine alone, <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> alone, or fluoropyrimidine plus bevacizumab) [<a href="#rid113">113</a>]. Different induction regimens were used in the different trials, including an oxaliplatin-based regimen in nine [<a href="#rid81">81,100-106,114,115</a>], an irinotecan-based regimen in two [<a href="#rid112">112,116</a>], and mixed regimens in one trial [<a href="#rid106">106</a>].</p><p></p><p class="bulletIndent1">Comparisons of any maintenance therapy versus observation demonstrated that maintenance therapy was associated with improved PFS in both direct (HR 0.63, 95% CI 0.45-0.86) and indirect analyses (HR 0.58, 95% CI 0.43-0.77), but the effect on overall survival was not significant (HR for the indirect analysis 0.91, 95% CI 0.83-1.01). Analyses of each specific maintenance strategy (fluoropyrimidine alone, <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> alone, fluoropyrimidine plus bevacizumab) versus observation alone also found improved PFS but not overall survival for all comparisons.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similarly, an individual patient data meta-analysis of more than 4000 patients enrolled on nine trials evaluating intermittent therapy after successful completion of induction therapy (six with planned stopping of all therapy, the other three discontinuing <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> with continuation of the other regimen components as maintenance therapy) also concluded that a complete break in therapy did not adversely impact survival [<a href="#rid117">117</a>]. The overall analysis of intermittent versus continuous therapy showed no significant overall survival detriment from intermittent therapy (HR 1.03, 95% CI 0.93-1.14), whether from complete break (HR 1.04, 95% CI 0.87-1.26) or maintenance (HR 0.99, 95% CI 0.87-1.13). PFS results were broadly consistent with the overall survival results. In a preplanned analysis, thrombocytosis was confirmed as a poor prognostic factor, but it did not predict for inferior survival from a complete treatment break compared with continuous therapy (interaction HR 0.97, 95% CI 0.66-1.40).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Additional data are available from the randomized FOCUS4-N trial, in which 254 patients with stable or responding disease after 16 weeks of induction therapy with a variety of regimens were randomly assigned to a complete break in therapy with active monitoring versus single-agent <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a> (1250 mg/m<sup>2</sup> twice daily on days 1 through 14 of each 21-day cycle), until progression [<a href="#rid118">118</a>]. Maintenance therapy with capecitabine doubled the time to progression and return to full-dose chemotherapy (median PFS 3.88 versus 1.87 months, HR 0.40, 95% CI 0.21-0.75), but had no impact on median overall survival (14.8 versus 15.2 months, adjusted HR 0.93, 95% CI 0.69-1.27). Furthermore, those assigned to maintenance capecitabine had significant higher rates of cumulative toxicity, especially diarrhea, fatigue, nausea, and palmar plantar erythrodysesthesia, although these were primarily low grade.</p><p></p><p class="headingAnchor" id="H183911707"><span class="h1">ASSESSING TREATMENT RESPONSE</span><span class="headingEndMark"> — </span>During chemotherapy, response is typically assessed by periodic assay (every one to three months) of serum carcinoembryonic antigen (CEA) levels, if initially elevated, and interval radiographic evaluation (typically every 8 to 12 weeks, or as prompted by a rising CEA level). Although persistently rising CEA levels are highly correlated with disease progression, confirmatory radiologic confirmatory studies should be obtained prior to a change in therapeutic strategy, with the notable exception of confirmed peritoneal carcinomatosis that is not radiographically measurable.</p><p class="headingAnchor" id="H2775591041"><span class="h2">Radiographic response</span><span class="headingEndMark"> — </span>Radiographic tumor response is usually quantified using Response Evaluation Criteria In Solid Tumors (RECIST)  (<a class="graphic graphic_table graphicRef74693" href="/z/d/graphic/74693.html" rel="external">table 3</a>) [<a href="#rid119">119,120</a>].</p><p>Immunotherapy using immune checkpoint inhibitors is increasingly being integrated into the care of patients with mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) mCRC. (See  <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'Patients with deficient DNA mismatch repair/microsatellite unstable tumors'</a> and  <a class="medical medical_review" href="/z/d/html/129349.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy", section on 'Microsatellite unstable/deficient mismatch repair tumors'</a>.)</p><p>Individuals treated with immune checkpoint inhibitors for dMMR/MSI-H mCRC can have pseudoprogression [<a href="#rid121">121</a>], and objective response criteria specifically developed for these drugs should be used (eg, immune-modified RECIST [imRECIST]  (<a class="graphic graphic_table graphicRef116649" href="/z/d/graphic/116649.html" rel="external">table 4</a>)). (See  <a class="medical medical_review" href="/z/d/html/99637.html" rel="external">"Principles of cancer immunotherapy", section on 'Immunotherapy response criteria'</a>.)</p><p class="headingAnchor" id="H3631960828"><span class="h2">Serum tumor markers</span><span class="headingEndMark"> — </span>If initially elevated, a 50 percent or greater declines in CEA from baseline to first restaging can predict disease nonprogression and correlate with favorable long-term outcomes [<a href="#rid122">122</a>]. On the other hand, persistently rising CEA levels (particularly rapidly rising levels [<a href="#rid123">123</a>]) are highly correlated with disease progression [<a href="#rid124">124,125</a>]. However, confirmatory radiologic studies are generally recommended in both settings, particularly if a change in therapeutic strategy is being considered because of a rising CEA. Caution should be used when interpreting a rising CEA level during the first four to six weeks of a new therapy, since spurious early elevation in serum CEA may occur, especially after <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> [<a href="#rid126">126-128</a>].</p><p>Circulating tumor DNA (ctDNA) is the fraction of circulating DNA that is derived from a patient's cancer. Colorectal cancers shed DNA into the blood, and interest in using ctDNA as a surrogate indicator of treatment response has grown as techniques to detect and quantify such DNA have improved. A meta-analysis of 24 studies on patients with mCRC reporting on the predictive or prognostic value of ctDNA concluded that a small or no early decrease in ctDNA levels during treatment was associated with short progression-free and overall survival, but the majority of included studies had a high risk of bias [<a href="#rid129">129</a>].</p><p>Few large prospective validation studies have been performed on ctDNA-based treatment monitoring. At least in advanced breast cancer, there are some data that suggest that ctDNA responses do not always parallel imaging-based responses [<a href="#rid130">130</a>], and no studies convincingly demonstrate improved patient outcomes or any cost savings when compared with standard of care monitoring approaches.</p><p>Thus, in our view, there is not yet enough known about the mechanisms controlling ctDNA change and how well radiologic responses or CEA changes and ctDNA markers correlate with each other to understand whether ctDNA can replace or supplement periodic assay of CEA or radiologic assessment, and the clinical utility of serial assay of ctDNA during remains uncertain. This position is consistent with a year 2018 joint review of the utility of ctDNA analysis in patients with cancer by American Society of Clinical Oncology and the College of American Pathologists, which concluded that there is insufficient evidence of clinical validity and utility for the majority of ctDNA assays in advanced cancer [<a href="#rid131">131</a>]. However, this remains an active area of research with a number of ongoing studies that should impact information on the potential future utility of ctDNA analysis in this setting.</p><p class="headingAnchor" id="H4022878823"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115274.html" rel="external">"Society guideline links: Colorectal cancer"</a>.)</p><p class="headingAnchor" id="H10072018"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15412.html" rel="external">"Patient education: Colon and rectal cancer (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/874.html" rel="external">"Patient education: Colon and rectal cancer (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/860.html" rel="external">"Patient education: Colorectal cancer treatment; metastatic cancer (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H9659249"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Available agents</strong> – Many systemic agents are used to treat metastatic colorectal cancer (mCRC), in combination with other drugs and as monotherapy. These include chemotherapy (<a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> [FU], <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a>, <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a>, among others), antiangiogenic agents, molecularly targeted agents, and immune checkpoint inhibitors. (See <a class="local">'Systemic therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Predictive biomarkers</strong> – Predictive biomarkers (specific targetable molecular alterations found in colorectal cancer) are often used to select therapy for mCRC. (See <a class="local">'Predictive biomarkers'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>RAS</em></strong><strong> and </strong><strong><em>BRAF</em></strong><strong> wild-type disease</strong> – Patients with mCRC whose tumors are <em>RAS</em> and <em>BRAF</em> V600E wild-type are eligible for treatment with EGFR inhibitors (<a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> or <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a>). (See  <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'RAS/BRAF wild-type tumors'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>RAS</em></strong><strong> mutant disease</strong> – <em>RAS </em>mutated mCRC is resistant to EGFR inhibitors (<a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> or <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a>) and we do not use them in these cancers, either alone or in addition to chemotherapy. (See <a class="local">'Impact of RAS status on the use of EGFR inhibitors'</a> above and  <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'RAS or BRAF mutant tumors'</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>BRAF</em></strong><strong> V600E mutant disease</strong> – <em>BRAF</em> V600E mutated mCRC shows resistance to EGFR inhibitors, and we do not use them as single agents for these cancers, due to limited benefit in randomized trials. (See <a class="local">'BRAF mutations'</a> above.)</p><p></p><p class="bulletIndent2">However, for those with treatment-refractory disease, <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> or <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a> can be combined with <a class="drug drug_general" data-topicid="118325" href="/z/d/drug information/118325.html" rel="external">encorafenib</a>, a BRAF inhibitor, to overcome tumor resistance to EGFR inhibitors. (See  <a class="medical medical_review" href="/z/d/html/129349.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy", section on 'RAS wild-type, BRAF mutated tumors'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other clinically relevant biomarkers</strong> – Other clinically relevant biomarkers include mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H), HER2 expression, and molecular alterations in <em>NTRK</em>. (See <a class="local">'dMMR or MSI-H tumors'</a> above and <a class="local">'HER2-positive tumors'</a> above and <a class="local">'TRK-fusion-positive tumors'</a> above.)</p><p></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment goals</strong> – Some patients with stage IV disease can be surgically cured of their disease, and the goal of initial chemotherapy is maximal reduction in tumor burden. For most, treatment is palliative, and the goals are to prolong overall survival and maintain quality of life (QOL) for as long as possible. (See <a class="local">'Treatment goals'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing of therapy</strong> – For most patients, we suggest early rather than deferred initiation of chemotherapy, and when possible, before patients become symptomatic (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Timing of systemic therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of initial therapy</strong> – The optimal duration of initial chemotherapy for unresectable mCRC is controversial. The decision to permit treatment breaks for responding patients must be individualized and based upon the regimen being used, tolerance of and response to chemotherapy, disease bulk and location, symptomatology, and patient preference. For many patients with chemotherapy responsive disease who do not have bulky or severely symptomatic disease, intermittent rather than continuous therapy may mitigate treatment-related toxicity, and does not appear to adversely impact overall survival. (See <a class="local">'Continuous versus intermittent therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients receiving</strong> <strong>oxaliplatin</strong> – For most patients who are responding to an oxaliplatin-based initial regimen, we suggest discontinuing <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> before the onset of severe neurotoxicity (usually after three to four months of therapy) while continuing the other agents in the regimen (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Continuing oxaliplatin is a reasonable alternative for patients who have an ongoing response and no clinically significant neuropathy. (See <a class="local">'Patients receiving oxaliplatin'</a> above.)</p><p></p><p class="bulletIndent2">A complete break in therapy is also a valid option, particularly if a complete clinical response is observed or for those with small-volume metastatic disease who have a partial response or stable disease to the initial course of chemotherapy. Decision-making should also consider patient preference. In such cases, close follow-up with tumor assessment at two-month intervals and early resumption of chemotherapy at the first sign of progression is recommended. (See <a class="local">'Complete break in therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients receiving</strong> <strong>irinotecan</strong> – The advantages of intermittent treatment with irinotecan-based regimens are less clear, and for most patients, we continue treatment for as long as tolerability and tumor shrinkage continue. Intermittent treatment is an option for responding patients who desire a break in therapy, particularly for those receiving concomitant therapy with an anti-EGFR agent. (See <a class="local">'Irinotecan'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Response assessment</strong> – Response to chemotherapy is typically assessed by periodic assay of serum carcinoembryonic antigen (CEA) levels, if initially elevated, and interval radiographic evaluation. Although persistently rising CEA levels are highly correlated with disease progression, confirmatory radiologic confirmatory studies should be obtained prior to a change in therapeutic strategy, with the notable exception of confirmed peritoneal carcinomatosis that is not radiographically measurable. (See <a class="local">'Assessing treatment response'</a> above.)</p><p></p><p class="headingAnchor" id="H392471870"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Axel Grothey, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Allegra CJ, Rumble RB, Hamilton SR, et al. Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. J Clin Oncol 2016; 34:179.</a></li><li class="breakAll">National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf (Accessed on July 25, 2023).</li><li class="breakAll">NCCN Clinical Practice Guidelines in Oncology. Available at: https://www.nccn.org/professionals/physician_gls/default.aspx (Accessed on October 27, 2021).</li><li class="breakAll">List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools). U.S. Food and Drug Administration. https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools (Accessed on August 04, 2022).</li><li><a class="nounderline abstract_t">Han CB, Li F, Ma JT, Zou HW. Concordant KRAS mutations in primary and metastatic colorectal cancer tissue specimens: a meta-analysis and systematic review. Cancer Invest 2012; 30:741.</a></li><li><a class="nounderline abstract_t">Peeters M, Kafatos G, Taylor A, et al. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials. Eur J Cancer 2015; 51:1704.</a></li><li><a class="nounderline abstract_t">Lee KH, Kim JS, Lee CS, Kim JY. KRAS discordance between primary and recurrent tumors after radical resection of colorectal cancers. J Surg Oncol 2015; 111:1059.</a></li><li><a class="nounderline abstract_t">Chakravarty D, Johnson A, Sklar J, et al. Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol 2022; 40:1231.</a></li><li><a class="nounderline abstract_t">Thierry AR, El Messaoudi S, Mollevi C, et al. Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment. Ann Oncol 2017; 28:2149.</a></li><li><a class="nounderline abstract_t">Spindler KG, Boysen AK, Pallisgård N, et al. Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. Oncologist 2017; 22:1049.</a></li><li><a class="nounderline abstract_t">García-Foncillas J, Alba E, Aranda E, et al. Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review. Ann Oncol 2017; 28:2943.</a></li><li><a class="nounderline abstract_t">Normanno N, Esposito Abate R, Lambiase M, et al. RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial. Ann Oncol 2018; 29:112.</a></li><li><a class="nounderline abstract_t">Grasselli J, Elez E, Caratù G, et al. Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer. Ann Oncol 2017; 28:1294.</a></li><li><a class="nounderline abstract_t">Vidal J, Muinelo L, Dalmases A, et al. Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients. Ann Oncol 2017; 28:1325.</a></li><li><a class="nounderline abstract_t">Hao YX, Fu Q, Guo YY, et al. Effectiveness of circulating tumor DNA for detection of KRAS gene mutations in colorectal cancer patients: a meta-analysis. Onco Targets Ther 2017; 10:945.</a></li><li><a class="nounderline abstract_t">Kagawa Y, Elez E, García-Foncillas J, et al. Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for RAS Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study. Clin Cancer Res 2021; 27:2515.</a></li><li><a class="nounderline abstract_t">de Reyniès A, Boige V, Milano G, et al. KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature. J Clin Oncol 2008; 26:2228.</a></li><li><a class="nounderline abstract_t">Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360:1408.</a></li><li><a class="nounderline abstract_t">Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27:663.</a></li><li><a class="nounderline abstract_t">Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359:1757.</a></li><li><a class="nounderline abstract_t">Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25:3230.</a></li><li><a class="nounderline abstract_t">Lièvre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26:374.</a></li><li><a class="nounderline abstract_t">Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:1626.</a></li><li><a class="nounderline abstract_t">Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007; 96:1166.</a></li><li><a class="nounderline abstract_t">Loupakis F, Ruzzo A, Cremolini C, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009; 101:715.</a></li><li><a class="nounderline abstract_t">Richman SD, Seymour MT, Chambers P, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009; 27:5931.</a></li><li><a class="nounderline abstract_t">Tabernero J, Cervantes A, Rivera F, et al. Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. J Clin Oncol 2010; 28:1181.</a></li><li><a class="nounderline abstract_t">Dahabreh IJ, Terasawa T, Castaldi PJ, Trikalinos TA. Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann Intern Med 2011; 154:37.</a></li><li><a class="nounderline abstract_t">Tougeron D, Lecomte T, Pagès JC, et al. Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer. Ann Oncol 2013; 24:1267.</a></li><li><a class="nounderline abstract_t">Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28:4697.</a></li><li><a class="nounderline abstract_t">Tejpar S, Celik I, Schlichting M, et al. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 2012; 30:3570.</a></li><li><a class="nounderline abstract_t">Gajate P, Sastre J, Bando I, et al. Influence of KRAS p.G13D mutation in patients with metastatic colorectal cancer treated with cetuximab. Clin Colorectal Cancer 2012; 11:291.</a></li><li><a class="nounderline abstract_t">Peeters M, Douillard JY, Van Cutsem E, et al. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol 2013; 31:759.</a></li><li><a class="nounderline abstract_t">Mao C, Huang YF, Yang ZY, et al. KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis. Cancer 2013; 119:714.</a></li><li><a class="nounderline abstract_t">Schirripa M, Loupakis F, Lonardi S, et al. Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer. Ann Oncol 2015; 26:2503.</a></li><li><a class="nounderline abstract_t">Rowland A, Dias MM, Wiese MD, et al. Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours. Eur J Cancer 2016; 55:122.</a></li><li><a class="nounderline abstract_t">Segelov E, Thavaneswaran S, Waring PM, et al. Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study. J Clin Oncol 2016; 34:2258.</a></li><li><a class="nounderline abstract_t">Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369:1023.</a></li><li><a class="nounderline abstract_t">Fornaro L, Lonardi S, Masi G, et al. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). Ann Oncol 2013; 24:2062.</a></li><li><a class="nounderline abstract_t">De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11:753.</a></li><li><a class="nounderline abstract_t">Schwartzberg LS, Rivera F, Karthaus M, et al. Analysis of KRAS/NRAS mutations in PEAK: A randomized phase II study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild‑type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC). J Clin Oncol 2013; 31S:ASCO #3631.</a></li><li><a class="nounderline abstract_t">Stintzing S, Jung A, Rossius L, Modest DP. Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. Eur J Cancer 2013; 49S:ECC #17.</a></li><li><a class="nounderline abstract_t">Peeters M, Oliner KS, Price TJ, et al. Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer. Clin Cancer Res 2015; 21:5469.</a></li><li><a class="nounderline abstract_t">Sorich MJ, Wiese MD, Rowland A, et al. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol 2015; 26:13.</a></li><li class="breakAll">Jessup JM, Goldberg RM, Asare EA, et al. Colon and Rectum. In: AJCC Cancer Staging Manual, 8th ed, Amin MB (Ed), AJCC, Chicago 2017. p.251.</li><li><a class="nounderline abstract_t">Cervantes A, Adam R, Roselló S, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023; 34:10.</a></li><li><a class="nounderline abstract_t">Yuan ZX, Wang XY, Qin QY, et al. The prognostic role of BRAF mutation in metastatic colorectal cancer receiving anti-EGFR monoclonal antibodies: a meta-analysis. PLoS One 2013; 8:e65995.</a></li><li><a class="nounderline abstract_t">Lochhead P, Kuchiba A, Imamura Y, et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst 2013; 105:1151.</a></li><li><a class="nounderline abstract_t">Van Cutsem E, Köhne CH, Láng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29:2011.</a></li><li><a class="nounderline abstract_t">Maughan TS, Adams RA, Smith CG, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377:2103.</a></li><li><a class="nounderline abstract_t">Tran B, Kopetz S, Tie J, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 2011; 117:4623.</a></li><li><a class="nounderline abstract_t">Venderbosch S, Nagtegaal ID, Maughan TS, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res 2014; 20:5322.</a></li><li><a class="nounderline abstract_t">Chu JE, Johnson B, Kugathasan L, et al. Population-based Screening for BRAFV600E in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor Prognosis. Clin Cancer Res 2020; 26:4599.</a></li><li><a class="nounderline abstract_t">Pietrantonio F, Petrelli F, Coinu A, et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer 2015; 51:587.</a></li><li><a class="nounderline abstract_t">Rowland A, Dias MM, Wiese MD, et al. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer 2015; 112:1888.</a></li><li><a class="nounderline abstract_t">Cohen R, Liu H, Fiskum J, et al. BRAF V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database. J Natl Cancer Inst 2021; 113:1386.</a></li><li><a class="nounderline abstract_t">Stintzing S, Heinrich K, Tougeron D, et al. FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study. J Clin Oncol 2023; 41:4143.</a></li><li><a class="nounderline abstract_t">Jones JC, Renfro LA, Al-Shamsi HO, et al. Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. J Clin Oncol 2017; :JCO2016714394.</a></li><li><a class="nounderline abstract_t">Shinozaki E, Yoshino T, Yamazaki K, et al. Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study. Br J Cancer 2017; 117:1450.</a></li><li><a class="nounderline abstract_t">Johnson B, Loree JM, Jacome AA, et al. Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer. JCO Precis Oncol 2019; 3.</a></li><li><a class="nounderline abstract_t">Yaeger R, Kotani D, Mondaca S, et al. Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer. Clin Cancer Res 2019; 25:7089.</a></li><li><a class="nounderline abstract_t">Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6:279.</a></li><li><a class="nounderline abstract_t">Laurent-Puig P, Cayre A, Manceau G, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009; 27:5924.</a></li><li><a class="nounderline abstract_t">Cappuzzo F, Varella-Garcia M, Finocchiaro G, et al. Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. Br J Cancer 2008; 99:83.</a></li><li><a class="nounderline abstract_t">Italiano A, Follana P, Caroli FX, et al. Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number. Ann Surg Oncol 2008; 15:649.</a></li><li><a class="nounderline abstract_t">Personeni N, Fieuws S, Piessevaux H, et al. Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. Clin Cancer Res 2008; 14:5869.</a></li><li><a class="nounderline abstract_t">Randon G, Yaeger R, Hechtman JF, et al. EGFR Amplification in Metastatic Colorectal Cancer. J Natl Cancer Inst 2021; 113:1561.</a></li><li><a class="nounderline abstract_t">Weeks JC, Catalano PJ, Cronin A, et al. Patients' expectations about effects of chemotherapy for advanced cancer. N Engl J Med 2012; 367:1616.</a></li><li class="breakAll">Petrelli NJ. Plenary program discussion. 43rd Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 4, 2007.</li><li><a class="nounderline abstract_t">Folprecht G, Grothey A, Alberts S, et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005; 16:1311.</a></li><li><a class="nounderline abstract_t">Grothey A, Hedrick EE, Mass RD, et al. Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol 2008; 26:183.</a></li><li><a class="nounderline abstract_t">Siena S, Peeters M, Van Cutsem E, et al. Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. Br J Cancer 2007; 97:1469.</a></li><li><a class="nounderline abstract_t">Giessen C, Laubender RP, Ankerst DP, et al. Progression-free survival as a surrogate endpoint for median overall survival in metastatic colorectal cancer: literature-based analysis from 50 randomized first-line trials. Clin Cancer Res 2013; 19:225.</a></li><li><a class="nounderline abstract_t">Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22:1209.</a></li><li><a class="nounderline abstract_t">Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 2005; 23:9441.</a></li><li><a class="nounderline abstract_t">Abrams TA, Meyer G, Schrag D, et al. Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer. J Natl Cancer Inst 2014; 106:djt371.</a></li><li><a class="nounderline abstract_t">Tang PA, Bentzen SM, Chen EX, Siu LL. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 2007; 25:4562.</a></li><li><a class="nounderline abstract_t">Buyse M, Burzykowski T, Carroll K, et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 2007; 25:5218.</a></li><li><a class="nounderline abstract_t">Shi Q, de Gramont A, Grothey A, et al. Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. J Clin Oncol 2015; 33:22.</a></li><li><a class="nounderline abstract_t">Eng C, Maurel J, Scheithauer W, et al. Impact on quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplatin-based therapy: The EPIC trial. J Clin Oncol 2007; 25S: ASCO #4003.</a></li><li><a class="nounderline abstract_t">Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. J Clin Oncol 2006; 24:394.</a></li><li><a class="nounderline abstract_t">Allegra C, Blanke C, Buyse M, et al. End points in advanced colon cancer clinical trials: a review and proposal. J Clin Oncol 2007; 25:3572.</a></li><li><a class="nounderline abstract_t">Goldberg RM, Rothenberg ML, Van Cutsem E, et al. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 2007; 12:38.</a></li><li><a class="nounderline abstract_t">Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol 1992; 10:904.</a></li><li><a class="nounderline abstract_t">Scheithauer W, Rosen H, Kornek GV, et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993; 306:752.</a></li><li><a class="nounderline abstract_t">Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ 2000; 321:531.</a></li><li><a class="nounderline abstract_t">Sanoff HK, Sargent DJ, Campbell ME, et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol 2008; 26:5721.</a></li><li><a class="nounderline abstract_t">Renouf DJ, Lim HJ, Speers C, et al. Survival for metastatic colorectal cancer in the bevacizumab era: a population-based analysis. Clin Colorectal Cancer 2011; 10:97.</a></li><li><a class="nounderline abstract_t">Jawed I, Wilkerson J, Prasad V, et al. Colorectal Cancer Survival Gains and Novel Treatment Regimens: A Systematic Review and Analysis. JAMA Oncol 2015; 1:787.</a></li><li><a class="nounderline abstract_t">Shen C, Tannenbaum D, Horn R, et al. Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016: A Systematic Review. JAMA Netw Open 2022; 5:e2213588.</a></li><li><a class="nounderline abstract_t">Dy GK, Hobday TJ, Nelson G, et al. Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a North Central Cancer Treatment Group review of 3811 patients, N0144. Clin Colorectal Cancer 2009; 8:88.</a></li><li><a class="nounderline abstract_t">Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15:1065.</a></li><li><a class="nounderline abstract_t">Ackland SP, Jones M, Tu D, et al. A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer. Br J Cancer 2005; 93:1236.</a></li><li><a class="nounderline abstract_t">Voskoboynik M, Bae S, Ananda S, et al. An initial watch and wait approach is a valid strategy for selected patients with newly diagnosed metastatic colorectal cancer. Ann Oncol 2012; 23:2633.</a></li><li><a class="nounderline abstract_t">Chambers P, Daniels SH, Thompson LC, Stephens RJ. Chemotherapy dose reductions in obese patients with colorectal cancer. Ann Oncol 2012; 23:748.</a></li><li><a class="nounderline abstract_t">Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2021; 39:2037.</a></li><li><a class="nounderline abstract_t">Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26:2013.</a></li><li><a class="nounderline abstract_t">Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23.</a></li><li><a class="nounderline abstract_t">de Gramont A, Buyse M, Abrahantes JC, et al. Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. J Clin Oncol 2007; 25:3224.</a></li><li><a class="nounderline abstract_t">Chibaudel B, Maindrault-Goebel F, Lledo G, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 2009; 27:5727.</a></li><li><a class="nounderline abstract_t">Hochster HS, Grothey A, Hart L, et al. Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT. Ann Oncol 2014; 25:1172.</a></li><li><a class="nounderline abstract_t">Simkens LH, van Tinteren H, May A, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet 2015; 385:1843.</a></li><li><a class="nounderline abstract_t">Hegewisch-Becker S, Graeven U, Lerchenmüller CA, et al. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol 2015; 16:1355.</a></li><li><a class="nounderline abstract_t">Yalcin S, Uslu R, Dane F, et al. Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III 'Stop and Go' study results--a Turkish Oncology Group Trial. Oncology 2013; 85:328.</a></li><li><a class="nounderline abstract_t">Díaz-Rubio E, Gómez-España A, Massutí B, et al. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist 2012; 17:15.</a></li><li><a class="nounderline abstract_t">Koeberle D, Betticher DC, von Moos R, et al. Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06). Ann Oncol 2015; 26:709.</a></li><li><a class="nounderline abstract_t">Aranda E, García-Alfonso P, Benavides M, et al. First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study. Eur J Cancer 2018; 101:263.</a></li><li><a class="nounderline abstract_t">Pietrantonio F, Morano F, Corallo S, et al. Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol 2019; 5:1268.</a></li><li><a class="nounderline abstract_t">Modest DP, Karthaus M, Fruehauf S, et al. Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212). J Clin Oncol 2022; 40:72.</a></li><li><a class="nounderline abstract_t">Labianca R, Sobrero A, Isa L, et al. Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial. Ann Oncol 2011; 22:1236.</a></li><li class="breakAll">Avallone A, Giuliani F, Nasto F, et al. Randomized intermittent or continuous panitumumab plus FOLFIRI (FOLFIRI/PANI) for first-line treatment of patients (pts) with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): The IMPROVE study (abstract). Abstract available online at https://meetings.asco.org/2022-asco-annual-meeting/14359?presentation=208329#208329 (Accessed on June 09, 2022).</li><li><a class="nounderline abstract_t">Aparicio T, Ghiringhelli F, Boige V, et al. Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9). J Clin Oncol 2018; 36:674.</a></li><li><a class="nounderline abstract_t">Sonbol MB, Mountjoy LJ, Firwana B, et al. The Role of Maintenance Strategies in Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis of Randomized Clinical Trials. JAMA Oncol 2020; 6:e194489.</a></li><li><a class="nounderline abstract_t">Adams RA, Meade AM, Seymour MT, et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol 2011; 12:642.</a></li><li><a class="nounderline abstract_t">Luo HY, Li YH, Wang W, et al. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. Ann Oncol 2016; 27:1074.</a></li><li><a class="nounderline abstract_t">Berry SR, Cosby R, Asmis T, et al. Continuous versus intermittent chemotherapy strategies in metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncol 2015; 26:477.</a></li><li><a class="nounderline abstract_t">Adams R, Goey K, Chibaudel B, et al. Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis. Cancer Treat Rev 2021; 99:102226.</a></li><li><a class="nounderline abstract_t">Adams RA, Fisher DJ, Graham J, et al. Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial. J Clin Oncol 2021; 39:3693.</a></li><li><a class="nounderline abstract_t">Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228.</a></li><li><a class="nounderline abstract_t">Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205.</a></li><li><a class="nounderline abstract_t">Colle R, Radzik A, Cohen R, et al. Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. Eur J Cancer 2021; 144:9.</a></li><li><a class="nounderline abstract_t">Gulhati P, Yin J, Pederson L, et al. Threshold Change in CEA as a Predictor of Non-Progression to First-Line Systemic Therapy in Metastatic Colorectal Cancer Patients With Elevated CEA. J Natl Cancer Inst 2020; 112:1127.</a></li><li><a class="nounderline abstract_t">Iwanicki-Caron I, Di Fiore F, Roque I, et al. Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer. J Clin Oncol 2008; 26:3681.</a></li><li><a class="nounderline abstract_t">Shani A, O'Connell MJ, Moertel CG, et al. Serial plasma carcinoembryonic antigen measurements in the management of metastatic colorectal carcinoma. Ann Intern Med 1978; 88:627.</a></li><li><a class="nounderline abstract_t">Trillet-Lenoir V, Chapuis F, Touzet S, et al. Any clinical benefit from the use of oncofoetal markers in the management of chemotherapy for patients with metastatic colorectal carcinomas? Clin Oncol (R Coll Radiol) 2004; 16:196.</a></li><li><a class="nounderline abstract_t">Sørbye H, Dahl O. Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to oxaliplatin combination chemotherapy: implications for tumor marker monitoring and guidelines. J Clin Oncol 2003; 21:4466.</a></li><li><a class="nounderline abstract_t">Ailawadhi S, Sunga A, Rajput A, et al. Chemotherapy-induced carcinoembryonic antigen surge in patients with metastatic colorectal cancer. Oncology 2006; 70:49.</a></li><li><a class="nounderline abstract_t">Strimpakos AS, Cunningham D, Mikropoulos C, et al. The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy. Ann Oncol 2010; 21:1013.</a></li><li><a class="nounderline abstract_t">Callesen LB, Hamfjord J, Boysen AK, et al. Circulating tumour DNA and its clinical utility in predicting treatment response or survival in patients with metastatic colorectal cancer: a systematic review and meta-analysis. Br J Cancer 2022; 127:500.</a></li><li><a class="nounderline abstract_t">García-Saenz JA, Ayllón P, Laig M, et al. Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging. BMC Cancer 2017; 17:210.</a></li><li><a class="nounderline abstract_t">Merker JD, Oxnard GR, Compton C, et al. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol 2018; 36:1631.</a></li></ol></div><div id="topicVersionRevision">Topic 15802 Version 75.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26438111" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26438111" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26438111" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26438111" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23075074" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Concordant KRAS mutations in primary and metastatic colorectal cancer tissue specimens: a meta-analysis and systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26049686" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26031776" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : KRAS discordance between primary and recurrent tumors after radical resection of colorectal cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35175857" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28911069" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28778958" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28945877" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28950295" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28368441" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28419195" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28243130" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Effectiveness of circulating tumor DNA for detection of KRAS gene mutations in colorectal cancer patients: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33602686" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for RAS Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18445856" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19339720" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19114683" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18946061" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : K-ras mutations and benefit from cetuximab in advanced colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17664471" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18202412" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18316791" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17375050" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19603018" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19884549" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20100964" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21200037" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23293113" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20921465" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22734028" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22537608" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Influence of KRAS p.G13D mutation in patients with metastatic colorectal cancer treated with cetuximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23182985" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22972628" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26371285" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26812186" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27114605" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24024839" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23666916" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20619739" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Analysis of KRAS/NRAS mutations in PEAK: A randomized phase II study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild‑type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26341920" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25115304" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25115304" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36307056" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23776587" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The prognostic role of BRAF mutation in metastatic colorectal cancer receiving anti-EGFR monoclonal antibodies: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23878352" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21502544" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21641636" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21456008" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25139339" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32571791" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Population-based Screening for BRAFV600E in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor Prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25673558" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25989278" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33734401" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : BRAF V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37352476" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28486044" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28972961" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31515458" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15863375" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19884556" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18577988" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17987340" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18794099" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33825902" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : EGFR Amplification in Metastatic Colorectal Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23094723" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Patients' expectations about effects of chemotherapy for advanced cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23094723" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Patients' expectations about effects of chemotherapy for advanced cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15870084" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18182660" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18040272" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23149819" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Progression-free survival as a surrogate endpoint for median overall survival in metastatic colorectal cancer: literature-based analysis from 50 randomized first-line trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15051767" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16361649" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24511107" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17876010" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18024867" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Progression-free survival is a surrogate for survival in advanced colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25385741" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Impact on quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplatin-based therapy: The EPIC trial</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16421419" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17704403" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : End points in advanced colon cancer clinical trials: a review and proposal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17227899" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : The continuum of care: a paradigm for the management of metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1588370" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7683942" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10968812" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19001325" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21859560" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Survival for metastatic colorectal cancer in the bevacizumab era: a population-based analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26181239" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Colorectal Cancer Survival Gains and Novel Treatment Regimens: A Systematic Review and Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35608860" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19739269" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a North Central Cancer Treatment Group review of 3811 patients, N0144.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25088940" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16265352" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22734008" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : An initial watch and wait approach is a valid strategy for selected patients with newly diagnosed metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21652579" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Chemotherapy dose reductions in obese patients with colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33939491" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18421054" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14665611" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17664470" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19786657" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24608198" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25862517" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26361971" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24247559" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III 'Stop and Go' study results--a Turkish Oncology Group Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22234633" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25605741" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30054049" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31268481" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34533973" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21078826" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21078826" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29346040" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31855256" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : The Role of Maintenance Strategies in Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis of Randomized Clinical Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21641867" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26940686" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25057174" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Continuous versus intermittent chemotherapy strategies in metastatic colorectal cancer: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34130171" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34516759" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19097774" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10655437" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33316636" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32191317" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Threshold Change in CEA as a Predictor of Non-Progression to First-Line Systemic Therapy in Metastatic Colorectal Cancer Patients With Elevated CEA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18669452" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/646245" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Serial plasma carcinoembryonic antigen measurements in the management of metastatic colorectal carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15191007" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Any clinical benefit from the use of oncofoetal markers in the management of chemotherapy for patients with metastatic colorectal carcinomas?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14645446" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to oxaliplatin combination chemotherapy: implications for tumor marker monitoring and guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16446549" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Chemotherapy-induced carcinoembryonic antigen surge in patients with metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19861580" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35440666" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Circulating tumour DNA and its clinical utility in predicting treatment response or survival in patients with metastatic colorectal cancer: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28330468" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29504847" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
